H.C. Wainwright Remains a Buy on Vascular Biogenics (VBLT)

By Jason Carr

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Vascular Biogenics (VBLTResearch Report), with a price target of $3.00. The company’s shares closed last Monday at $1.04.

According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -18.0% and a 21.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Trillium Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vascular Biogenics with a $3.00 average price target, implying a 200.0% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $2.00 price target.

See today’s analyst top recommended stocks >>

Based on Vascular Biogenics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.73 million. In comparison, last year the company had a GAAP net loss of $3.87 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.